# Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

> **NCT00112658** · PHASE2,PHASE3 · COMPLETED · sponsor: **UNICANCER** · enrollment: 342 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** fluorouracil
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** irinotecan hydrochloride
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00112658
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2010-06
- **Final completion:** 2010-06-30
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2021-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112658, "Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00112658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*